cdc-coteauxdegaronne
» » Anticholinergic therapy in obstructive airways disease
eBook Anticholinergic therapy in obstructive airways disease ePub

eBook Anticholinergic therapy in obstructive airways disease ePub

by Nicholas J. (ed) GROSS

  • ISBN: 0906534623
  • Subcategory: No category
  • Author: Nicholas J. (ed) GROSS
  • Publisher: Franklin Scientific; 1st ed edition (1993)
  • ePub book: 1392 kb
  • Fb2 book: 1195 kb
  • Other: lrf azw lrf mbr
  • Rating: 4.3
  • Votes: 864

Description

In the last 2 decades, anticholinergic agents have been generally regarded as the first-choice bronchodilator therapy .

In the last 2 decades, anticholinergic agents have been generally regarded as the first-choice bronchodilator therapy in the routine management of stable chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma. Anticholinergics are particularly important bronchodilators in COPD, because the vagal tone appears to be the only reversible component of airflow limitation in COPD.

Anticholinergic therapy in obstructive airways disease. by Nicholas J. ed. GROSS.

Anticholinergics are commonly used in the treatment of airway diseases. The use of anticholinergics in chronic obstructive pulmonary disease and in rhinitis are also considered. Multiple mechanisms related to changes in expression and function of inhibitory M2 muscarinic receptors on the airway parasympathetic nerves may be involved, and are discussed.

In:Gross NJ (ed): Anticholinergic therapy in obstructive airways disease. 1986) Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease. Am J Med 81 (Suppl 5A): 81–90Google Scholar. Franklin Scientific Publications, London, 105–115Google Scholar.

The anticholinergic effects from botanical preparations of the deadly nightshade family have been used for hundreds of years for the treatment of obstructive airway diseases

The anticholinergic effects from botanical preparations of the deadly nightshade family have been used for hundreds of years for the treatment of obstructive airway diseases. Nowadays, derivatives of the plant alkaloids with quaternary ammonium structure, ipratropium bromide and tiotropium bromide, are used, which retain the bronchodilator properties of the parent compounds but are much safer since they are poorly absorbed across biologic membranes. They are the bronchodilators of choice in the management of chronic obstructive pulmonary disease (COPD).

Presentation on theme: "Chronic Obstructive Pulmonary Disease: An. .GOLD Global Initiative for Chronic Obstructive Lung Disease. Adapted from Chest,23 with permission from the American College of Chest Physicians.

Presentation on theme: "Chronic Obstructive Pulmonary Disease: An Evidence-Based Approach to Treatment With a Focus on Anticholinergic Bronchodilation Nicholas J. Gross, MD,"- Presentation transcript . 4 FIGURE 3 Effects of tiotropium and formoterol plus tiotropium on mean forced expiratory volume in the first second of expiration (FEV1).

The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction

The prevalence of chronic airways diseases such as chronic obstructive pulmonary disease and asthma is increasing. They lead to symptoms such as a cough and shortness of breath, partially through bronchoconstriction. Inhaled anticholinergics are one of a number of treatments designed to treat bronchoconstriction in airways disease.

As such, anticholinergic therapy is used extensively and with a high degree of success in the treatment of this condition. The future for inhaled anticholinergic compounds for the treatment of chronic obstructive pulmonary disease appears to rest in their combination with other agents, such as beta2 agonists and phosphodiesterase-4 inhibitors. Nonselective anticholinergic agents might be the best choice, because M2 muscarinic receptors on airway smooth muscle inhibit the generation and accumulation of cyclic adenosine monophosphate.

Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Anticholinergic therapy in obstructive airways disease. London: Franklin Scientic Publications; 1993.